Lilly says it will bring its obesity pill to India

Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior company executive said on September 25, offering patients there a pill alternative to the injectable GLP-1 drugs that dominate the U.S. market ^[1]. Winselow Tucker, president of Lilly India, said at an industry conference in Mumbai that "there is promise for products like that in India, if it gets approved," but he did not give a launch timeline ^[1].

Orforglipron has not launched anywhere in the world yet. Lilly has said it plans to file for approval with regulators in the United States, Britain, the European Union, Japan, and China, but it was not immediately clear whether the company has started an approval process in India specifically ^[1]. The drug works through the same GLP-1 pathway as tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for weight loss ^[1].

Executives framed the pill format as a practical fix for India's market, where cold-chain storage and injector devices raise costs and where many patients avoid needles. Novo Nordisk India head Vikrant Shrotriya said people in India would rather take a tablet than inject a drug, and Tucker pointed to stigma and logistical hurdles that weigh on injectable treatments ^[1]. Recent trial data cited in the report showed orforglipron lowered blood sugar and weight more effectively than Novo Nordisk's older GLP-1 pill Rybelsus in adults with type 2 diabetes ^[1].

Both Lilly and Novo Nordisk executives said demand for obesity drugs in India is rising even without a pill option. Novo's Wegovy and Lilly's Mounjaro, both launched in India earlier this year, have seen sales double within months, according to Shrotriya ^[1].

Why it matters for patients

For U.S. patients, this news is mostly about timing and manufacturing scale, not immediate access. Orforglipron has not been approved or launched in any country, including the United States ^[1]. Lilly's stated regulatory filing plans cover the U.S., U.K., EU, Japan, and China, but the source does not say when any of those filings will happen or when a decision might come ^[1].

The India plan matters indirectly because it signals how Lilly is thinking about orforglipron's advantages as a pill: no cold-chain shipping, no injector pens, and potentially lower distribution costs ^[1]. Those same advantages, if the drug is approved, could eventually shape how it is priced and distributed in the U.S., though the source does not address U.S. pricing or insurance coverage.

The trial comparison mentioned — orforglipron outperforming Rybelsus on blood sugar and weight in adults with type 2 diabetes — is specific to that head-to-head result and does not describe outcomes against injectable drugs like Ozempic, Wegovy, Mounjaro, or Zepbound ^[1].

What happens next

The source does not include specific dates for Lilly's regulatory filings for orforglipron in the U.S., U.K., EU, Japan, or China, nor a timeline for any India launch ^[1]. Tucker said only that a India launch is possible if the drug wins approval there, without committing to a schedule ^[1]. Whether Lilly has begun the approval process with Indian regulators was not confirmed in the reporting ^[1].